Related Experiment Video
Updated: Sep 22, 2026

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow
Published on: July 10, 2017
Product choice and haemophilia treatment in the Netherlands
E P Mauser-Bunschoten1, G Roosendaal, H M van den Berg
1Van Creveldkliniek, University Medical Center Utrecht, The Netherlands. e.mauserbunschoten@digd.azu.nl
Abstract:
In the Netherlands, there is a free choice of product for the treatment of haemophilia. Which product is chosen depends on the following considerations: medical, psychological, availability of clotting products, economics and government guidelines. Since the introduction of recombinant product in 1995, the percentage of Dutch patients treated with it has increased from 8% in 1995 to 20% in 1998. In 1999, an average of 48% of patients visiting the Van Creveldkliniek were treated with recombinant product. Children are more often treated with recombinant product than adults; 93% of children between 0 and 5 years, 53% of children between 6 and 20 years and 40% of adults are treated with recombinant product.
Related Concept Videos
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Rh Blood Group
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Venous Thrombosis III: Interprofessional Care

